NEW YORK (GenomeWeb) – A team from Harvard Medical School this week published the details of a novel approach to drug-target screening, combining the genome-editing technology CRISPR and the gene-silencing technology RNAi to identify three genes that appear to be essential to the growth of tumor cells but not normal cells.

According to the researchers, the method offers a number of advantages over conventional RNAi screening, which is limited by incomplete transfection, partial knockdown, and off-target effects, and therefore often requires secondary screening.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.